Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection (Q46121306)

19 December 2017

title

Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection (English)

1 reference

19 December 2017

1 reference

acute endophthalmitis

1 reference

O Artunay

1

1 reference

19 December 2017

E Yuzbasioglu

2

1 reference

19 December 2017

R Rasier

3

1 reference

19 December 2017

A Sengül

4

1 reference

19 December 2017

H Bahcecioglu

5

1 reference

19 December 2017

publication date

1 December 2009

1 reference

19 December 2017

published in

Eye

1 reference

19 December 2017

volume

23

1 reference

19 December 2017

issue

12

1 reference

19 December 2017

page(s)

2187-2193

1 reference

19 December 2017

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

cites work

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Endophthalmitis: a review of current evaluation and management

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Acute endophthalmitis following intravitreal triamcinolone acetonide injection

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Reducing the risk of endophthalmitis following intravitreal injections

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Testing intravitreal toxicity of bevacizumab (Avastin).

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Risks of intravitreous injection: a comprehensive review

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Infectious and noninfectious endophthalmitis after intravitreal bevacizumab.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Pegaptanib for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Postoperative endophthalmitis in association with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

National Outcomes of Cataract Extraction

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Changing trends in the microbiologic aspects of postcataract endophthalmitis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Infectious endophthalmitis. Review of 36 cases.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Intravitreal vancomycin and amikacin versus intravenous imipenem in the treatment of experimental Staphylococcus aureus endophthalmitis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Ten years after... are findings of the Endophthalmitis Vitrectomy Study still relevant today?

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Additional procedures after the initial vitrectomy or tap-biopsy in the endophthalmitis vitrectomy study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Vigamox: how good is its self-preservation?

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Topical 0.5% moxifloxacin prevents endophthalmitis in an intravitreal injection rabbit model

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.7

7 January 2021

Identifiers

DOI

10.1038/EYE.2009.7

1 reference

19 December 2017

1 reference

19 December 2017